XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 6 Months Ended
--- | ---
Dec. 31, 2024
Policy Text Block [Abstract] |
Investments | Investments: In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances. No such events or changes in circumstances were identified in the period ended December 31, 2024. The Company’s total investment of $15 million is included within Other assets on the Condensed Consolidated Balance Sheet. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. ​ ​ The investment in Wilson Wolf is accounted for as an equity method investment under ASC 323. The Company initially records its equity method investments at the amount of the Company’s investment and adjusts each period for the Company’s share of the investee’s income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. For the quarter ended December 31, 2024, the gain on the investment in Wilson Wolf was not material. In the six months ended December 31, 2024, there was $0.4 million of gain recorded on the Company’s Consolidated Statement of Earnings and Comprehensive Income related to the investment. The Company’s total investment of $241 million is included within Other assets on the Consolidated Balance Sheet.
Restructuring actions | Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2025 Restructuring Actions: In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Quarter Ended | ​ | Six Months Ended
​ | ​ | December 31, | ​ | December 31,
​ | ​ | 2024 | ​ | 2024
Cost of sales | ​ | $ | 2,691 | ​ | $ | 7,589
Selling, general and administrative(1) | ​ | ​ | 273 | ​ | ​ | 5,644
Total | ​ | $ | 2,964 | ​ | $ | 13,233
(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended December 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | Total
Protein Sciences | ​ | $ | 39 | ​ | $ | 2,755 | ​ | $ | 2,794
Diagnostics and Spatial Biology | ​ | ​ | (19) | ​ | ​ | — | ​ | ​ | (19)
Corporate | ​ | ​ | 185 | ​ | ​ | 4 | ​ | ​ | 189
Total | ​ | $ | 205 | ​ | $ | 2,759 | ​ | $ | 2,964
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended December 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | Total
Protein Sciences | ​ | $ | 2,313 | ​ | $ | 10,172 | ​ | $ | 12,485
Diagnostics and Spatial Biology | ​ | ​ | 425 | ​ | ​ | — | ​ | ​ | 425
Corporate | ​ | ​ | 319 | ​ | ​ | 4 | ​ | ​ | 323
Total | ​ | $ | 3,057 | ​ | $ | 10,176 | ​ | $ | 13,233
​ ​ The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance(1) |  | impairment and other(2) |  | Total
Expense incurred in the first quarter of 2025 | ​ | $ | 2,852 | ​ | $ | 7,417 | ​ | $ | 10,269
Cash payments | ​ | ​ | (189) | ​ | ​ | — | ​ | ​ | (189)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (7,417) | ​ | ​ | (7,417)
Accrued restructuring actions balance as of September 30, 2024 | ​ | $ | 2,663 | ​ | $ | — | ​ | $ | 2,663
Expense incurred in the second quarter of 2025 | ​ | ​ | 205 | ​ | ​ | 2,759 | ​ | ​ | 2,964
Cash payments | ​ | ​ | (1,211) | ​ | ​ | (335) | ​ | ​ | (1,546)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (2,424) | ​ | ​ | (2,424)
Accrued restructuring actions balance as of December 31, 2024 | ​ | $ | 1,657 | ​ | $ | — | ​ | $ | 1,657
(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. (2) Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites. Fiscal Year 2024 Restructuring Actions: In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the second quarter of fiscal 2025 as we incurred charges relating to our business held-for-sale and consulting fees related to optimizing efficiency. The Company is expecting to incur costs related to these actions through the end of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of an impairment test performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. There were no impairment charges related to the disposal group during the first half of fiscal 2025. During the quarter ended December 31, 2024, the Company entered into an agreement with a buyer to purchase the remaining inventory for approximately $8 million. As part of the arrangement, the Company and the buyer entered into a promissory note that will mature in February 2027 and agrees that the buyer shall pay in quarterly installments. As of December 31, 2024, the fair value of the note receivable was approximately $6 million and is included within Other current assets and Other assets on the Condensed Consolidated Balance Sheet. As of December 31, 2024, the assets remaining within the disposal group primarily include the land and building of $1.0 million, which is net of expected selling costs. These assets are actively marketed at a fair value based on market conditions such that the held-for-sale criterion are still met. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance sheet as of December 31, 2024 and June 30, 2024. ​ The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Quarter Ended | ​ | Six Months Ended
​ | ​ | December 31, | ​ | December 31,
​ | ​ | ​ | 2024 | ​ | ​ | 2023 | ​ | ​ | 2024 | ​ | ​ | 2023
Cost of sales | ​ | $ | — | ​ | $ | 1,174 | ​ | $ | — | ​ | $ | 1,174
Selling, general and administrative(1) | ​ | ​ | 323 | ​ | ​ | 10,250 | ​ | ​ | 1,076 | ​ | ​ | 10,250
Total | ​ | $ | 323 | ​ | $ | 11,424 | ​ | $ | 1,076 | ​ | $ | 11,424
(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. ​ Restructuring and restructuring-related costs by segment are as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended December 31,
​ | ​ | 2024 | ​ | 2023
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Protein Sciences | ​ | $ | (33) | ​ | $ | 10 | ​ | $ | — | ​ | $ | (23) | ​ | $ | 2,950 | ​ | $ | 472 | ​ | $ | 6,038 | ​ | $ | 9,460
Diagnostics and Spatial Biology | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 739 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 739
Corporate | ​ | ​ | — | ​ | ​ | 346 | ​ | ​ | — | ​ | ​ | 346 | ​ | ​ | 1,193 | ​ | ​ | 32 | ​ | ​ | — | ​ | ​ | 1,225
Total | ​ | $ | (33) | ​ | $ | 356 | ​ | $ | — | ​ | $ | 323 | ​ | $ | 4,882 | ​ | $ | 504 | ​ | $ | 6,038 | ​ | $ | 11,424
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended December 31,
​ | ​ | 2024 | ​ | 2023
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Protein Sciences | ​ | $ | (19) | ​ | $ | 50 | ​ | $ | — | ​ | $ | 31 | ​ | $ | 2,950 | ​ | $ | 472 | ​ | $ | 6,038 | ​ | $ | 9,460
Diagnostics and Spatial Biology | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 739 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 739
Corporate | ​ | ​ | (3) | ​ | ​ | 1,048 | ​ | ​ | — | ​ | ​ | 1,045 | ​ | ​ | 1,193 | ​ | ​ | 32 | ​ | ​ | — | ​ | ​ | 1,225
Total | ​ | $ | (22) | ​ | $ | 1,098 | ​ | $ | — | ​ | $ | 1,076 | ​ | $ | 4,882 | ​ | $ | 504 | ​ | $ | 6,038 | ​ | $ | 11,424
​ The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance(1) | ​ | ​ | and other(2) | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Expense incurred in the second quarter of 2024 | ​ | ​ | 4,882 | ​ | ​ | 504 | ​ | ​ | 6,038 | ​ | ​ | 11,424
Incremental expense incurred in the third quarter of 2024 | ​ | ​ | 133 | ​ | ​ | 1,140 | ​ | ​ | — | ​ | ​ | 1,273
Incremental expense incurred in the fourth quarter of 2024 | ​ | ​ | 409 | ​ | ​ | 4,737 | ​ | ​ | 15,926 | ​ | ​ | 21,072
Cash payments | ​ | ​ | (4,882) | ​ | ​ | (2,800) | ​ | ​ | — | ​ | ​ | (7,682)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (3,391) | ​ | ​ | (21,963) | ​ | ​ | (25,354)
Adjustments(3) | ​ | ​ | 219 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 219
Accrued restructuring actions balance as of June 30, 2024 | ​ | $ | 761 | ​ | $ | 190 | ​ | $ | — | ​ | $ | 952
Incremental expense incurred in the first quarter of 2025 | ​ | ​ | — | ​ | ​ | 753 | ​ | ​ | — | ​ | ​ | 753
Incremental expense incurred in the second quarter of 2025 | ​ | ​ | (33) | ​ | ​ | 356 | ​ | ​ | — | ​ | ​ | 323
Cash payments | ​ | ​ | (551) | ​ | ​ | (1,208) | ​ | ​ | — | ​ | ​ | (1,759)
Accrued restructuring actions balance as of December 31, 2024 | ​ | $ | 177 | ​ | $ | 92 | ​ | $ | — | ​ | $ | 269
(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. (2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. (3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. Protein Sciences Realignment In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 related to the refinement of employee severance payouts. Additional pre-tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, were as follows (in thousands): ​
​ | ​ | ​ | ​
​ | ​ | Employee
​ | ​ | severance
Accrued restructuring actions balance as of June 30, 2023 | ​ | $ | 897
Fiscal year 2024 cash payments | ​ | ​ | (1,118)
First quarter fiscal year 2024 adjustments(1) | ​ | ​ | 89
Second quarter fiscal year 2024 adjustments(1) | ​ | ​ | 132
Accrued restructuring actions balance as of June 30, 2024 | ​ | $ | —
(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.
Legal Matters | Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. ​ The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. ​ In August 2024, 794,400 shares of outstanding vested stock options related to former employees expired which have now been excluded from the Company’s dilutive EPS calculation for the period ended December 31, 2024. The expiration date of these options is currently under dispute. The total net pre-tax value of these options on the expiration date was approximately $32 million. As of December 31, 2024, the matter is under review and the Company is unable to estimate any future exposure related to this matter at this time. ​ The Company recognized $1.4 million and $1.7 million of certain litigation charges during the quarter and six months ended December 31, 2024. There was no comparable activity during the quarter and six months ended December 31, 2023. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in Other current liabilities and Other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for the legal matters included within our litigation charges line, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.
Recently Adopted Accounting Pronouncements and Relevant New Standards Issued Not Yet Adopted | Recently Adopted Accounting Pronouncements There were no accounting pronouncements adopted in the quarter ended December 31, 2024. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2024. ​ Relevant New Standards Issued Not Yet Adopted ​ In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ​ In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ​ In November 2024, the FASB issued ASU 2024-03, Income Statement –Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires incremental disclosures on purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2027 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ​ Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our unaudited condensed consolidated financial statements.

X
- Definition Disclosure of accounting policy for restructuring actions. + References No definition available. + Details
Name: | tech_RestructuringActionsPolicyTextBlock
Namespace Prefix: | tech_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of accounting policy for investment in financial asset. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details
Name: | us-gaap_InvestmentPolicyTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-2 + Details
Name: | us-gaap_LegalCostsPolicyTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References No definition available. + Details
Name: | us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PolicyTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration